Hjem › Multipelt myelom › California › San Francisco
Kliniske studier for Multipelt myelom i San Francisco, CA
15 studier for Multipelt myelom søker deltakere på steder i og rundt San Francisco (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RekruttererFase 1
- University of California San Francisco, San Francisco
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
RekruttererFase 2
- University of California San Francisco, San Francisco
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RekruttererFase 2
- University of California San Francisco, San Francisco
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 3
- University of California San Francisco, San Francisco
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekruttererFase 4
- University of California San Francisco, San Francisco
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 1/2
- UCSF, San Francisco
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekruttererFase 2
- Kaiser Permanente - South San Francisco Medical Center, San Francisco
- California Pacific Medical Center Research Institute, San Francisco
- Kaiser Permanente - San Francisco Medical Center, San Francisco
- og 1 flere
Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma
RekruttererFase 1
- University of California, San Francisco, San Francisco
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
RekruttererFase 2
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- UCSF, San Francisco
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekruttererFase 1
- UCSF Medical Center - Hematology and Blood and Marrow Transplant Clinic, San Francisco
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekruttererFase 1/2
- Research Site, San Francisco
Delayed Toxicities Post-CAR-T
RekruttererObservasjonsstudie
- UCSF Medical Center, San Francisco
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
RekruttererFase 1
- UCSF Helen Diller Medical Center at Parnassus Heights, San Francisco
Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
RekruttererFase 1
- University of Calfornia, San Francisco, San Francisco
Multipelt myelom-studier i andre byer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA41 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Chicago, IL22 studier
Andre studier i San Francisco
- Prostatakreft45 studier
- Brystkreft43 studier
- Ikke-småcellet lungekreft36 studier
- Kreft (alle typer)35 studier
- Hjertesvikt29 studier
- Metastatisk kreft28 studier
- Lungekreft23 studier
- Melanom22 studier
- Pankreaskreft20 studier
- Eggstokkreft19 studier
- Kolorektal kreft18 studier
- Kardiovaskulær sykdom18 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.